NCT00867009已完成2 期
A Phase 2 Study of Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) Other Than Predominantly Squamous Cell Histology
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 113
- 试验地点
- 1
- 主要终点
- Percentage of Participants With a Tumor Response (Objective Tumor Response Rate)
研究概览
简要总结
This study will estimate the response rate in patients with advanced or metastatic non-squamous Non-Small Cell Lung Cancer. Patients who don't progress after 4 to 6 cycles of induction treatment with pemetrexed, cisplatin and cetuximab will receive maintenance treatment with pemetrexed and cetuximab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must sign an informed consent document for clinical and translational research.
- •Patient must have locally advanced or metastatic nonsquamous Non-Small Cell Lung Cancer.
- •Patient must have biological tissue available from your diagnosis tumor for detection of some biomarkers (translational research).
- •Patient cannot be receiving nor have received any prior systemic anticancer therapy, immunotherapy, targeted therapy, or biological therapy for your lung cancer (except chemotherapy given after surgery if it has been completed more than one year before the study entry).
- •Patient is allowed to have had prior radiation therapy as long as it was not more than 25% of the bone marrow and did not include the whole pelvis. Prior radiation therapy should be completed at least 2 weeks prior to first study drug. Thoracic radiation must be completed more than 12 weeks before the study entry. You must be recovered from the toxic effects.
- •Patient must have at least 1 measurable tumor lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
- •Patient must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.
- •Test results assessing the function of blood forming tissue, kidneys, and liver must be satisfactory.
- •Females must be sterile, postmenopausal or on contraception.
- •Males must be on contraception or sterile (for example post-vasectomy).
排除标准
- •Patient cannot have symptomatic central nervous system metastases.
- •Patient cannot have an active infection or other serious condition that your doctor thinks would make you unable to participate.
- •Patient cannot have a serious cardiac condition, such as a heart attack, angina, or heart disease within 6 months of entering the trial.
- •Patient cannot have had a another form of cancer other than superficial basal cell and superficial squamous (skin) cell cancer, or carcinoma in situ of the cervix within the last 5 years.
- •Patient cannot have had significant neurologic or psychiatric disorders including dementia, seizures and bipolar disorder.
- •Patient cannot have moderate or severe peripheral neuropathy
- •Patient cannot have received treatment within 30 days with any experimental drug.
- •Patient cannot have had a major surgery within the last 4 weeks.
- •Patient cannot have previously received treatment with transduction inhibitors or Epidermal Growth Factor Receptor (EGFR)-targeting therapy.
- •Patient cannot have prior known allergic/hypersensitivity reaction to any of the components of study treatments.
- •Females cannot be pregnant or breastfeeding.
- •Patient is unable to stop taking more than 1.3 grams of aspirin on a daily basis or other aspirin like medication (non-steroidal antiinflammatory drugs: NSAIDs) for a few days during each cycle of therapy.
- •Patient is unable or unwilling to take folic acid, injections of vitamin B12, or corticosteroids.
- •Patient cannot have fluid around your lungs or in your abdomen (pleural effusions or ascites) that cannot be controlled by drainage or other procedures.
- •Patient cannot have received a yellow fever vaccination within the previous 30 days or plan to have it.
- •Patient cannot have known drug abuse.
研究组 & 干预措施
Induction/maintenance Therapy
Experimental
pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
干预措施: Cisplatin (Drug)
Induction/maintenance Therapy
Experimental
pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
干预措施: Pemetrexed (Drug)
Induction/maintenance Therapy
Experimental
pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
干预措施: Cetuximab (Drug)
结局指标
主要结局
Percentage of Participants With a Tumor Response (Objective Tumor Response Rate)
时间窗: From start of treatment until documented best response. (up to 18.9 months)
Response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions. Tumor response is presented as a percentage (%) and is the number of participants with a CR plus PR divided by the number of participants in the protocol qualified (PQ) population, then multiplied by 100.
次要结局
- The Percentage of Participants Still Living at One Year (One Year Survival Rate)(One year)
- The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])(From start of treatment until documented best tumor response (up to 18.9 months))
- Progression-free Survival (PFS)(From start of treatment until documented disease progression or death from any cause (up to 18.9 months))
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-NLEli Lilly and Company113
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-DEEli Lilly and Company125
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104EUCTR2008-004330-24-GREli Lilly and Company125
进行中（未招募）
1 期
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-ATEli Lilly and Company125
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125